◀ Back to MAPK3

APC — MAPK3

Text-mined interactions from Literome

da Silva et al., Anesthesiology 2004 (Reperfusion Injury) : IPC but not APC markedly activated ERK1/2 and p38 MAPK , which were abrogated by coadministration of the specific blockers ... Conversely, IPC and APC enhanced ERK1/2 activity after ischemia-reperfusion as compared to nonpreconditioned hearts, and IPC in addition enhanced p38 MAPK activity
Bretschneider et al., Circ Res 2007 (Carotid Stenosis) : APC induced ERK-1/2 phosphorylation was inhibited by an anti-EPCR antibody and by a cleavage site blocking anti-PAR-1 antibody, indicating that binding of APC to EPCR and cleavage of protease activated receptor-1 (PAR-1) were involved
O'Brien et al., Arterioscler Thromb Vasc Biol 2007 : APC also induced a significant increase in phosphorylation of ERK-1/2 , required to activate EGR-1 expression
Menschikowski et al., Thromb Res 2008 (Inflammation) : At the same time, APC increased the phosphorylation of ERK 1/2 and decreased NF-kappaB and C/EBP-beta DNA binding activities in these cells, as compared with respective stimulated controls ... Application of antibodies against EPCR and protease activated receptor-1 (PAR-1) reduced the APC induced ERK 1/2 activation and the treatment of cells with a PAR-1 antagonist diminished the sPLA ( 2 ) -IIA inhibition
Wang et al., Front Biosci (Elite Ed) 2011 (Brain Ischemia) : APC with sevofurane markedly improved neurological performance of stroke rats, significantly decreased infarct volume, and robustly suppressed activation of NF-kappa B and p38 MAPK , and expression of inflammatory cytokines
Caro-Gonzalez et al., J Cell Sci 2012 : Mitogen activated protein kinase ( MAPK/ERK ) regulates adenomatous polyposis coli during growth-factor induced cell extension